Live Analyst Rating Changes 28650 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Daniel Grosslight
Citi

Daniel Grosslight

Citi
Wall Street Analyst
★★★★☆
#713
on 13Foresight · ranked by our own returns
61%
Success Rate
+8.9%
Average Return
46 of 75 calls profitable · +5.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 61% of Daniel Grosslight's ratings turned a profit when each position was held for 1 year — averaging +8.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

67 Buy 36 Hold 14 Sell
Daniel's Stock Coverage 33 ratings · 2026-08-30
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
HIMS
Hims & Hers Health
 Aug 12, 2026 HOLD Buy
-2.9% avg upside
22 analysts
$33.00
14.37% Upside
 -3.8% ·
CAH
Cardinal Health
 Aug 12, 2026 BUY Strong Buy
-9.9% avg upside
30 analysts
$280.00
19.43% Upside
 +0.5% ·
GDRX
GoodRx Holdings
 Aug 11, 2026 BUY Buy
+266.8% avg upside
28 analysts
$5.00
41.73% Upside
 -7.1% ·
EVH
Evolent Health
 Aug 11, 2026 BUY Strong Buy
+110.8% avg upside
19 analysts
$6.00
30.50% Upside
 +17.1% ·
ZTS
Zoetis
 Aug 11, 2026 BUY Buy
+53.7% avg upside
23 analysts
$96.00
24.03% Upside
 +2.6% ·
AGL
Agilon Health
 Aug 11, 2026 HOLD Buy
-26.8% avg upside
26 analysts
$115.00
24.21% Upside
 +11.1% ·
ACH
Accendra Health
 Aug 11, 2026 HOLD Sell
+1278.1% avg upside
17 analysts
$1.50
24.03% Upside
 -4.0% ·
HCAT
Health Catalyst
 Aug 10, 2026 HOLD Buy
+243.1% avg upside
15 analysts
$2.00
25.88% Upside
 -11.1% ·
MCK
McKesson
 Aug 10, 2026 BUY Strong Buy
-13.9% avg upside
29 analysts
$1000.00
11.84% Upside
 +1.4% ·
NVST
Envista Holdings
 Aug 10, 2026 HOLD Buy
+12.8% avg upside
19 analysts
$32.00
17.91% Upside
 -2.7% ·
CTEV
Claritev
 Aug 10, 2026 BUY Strong Buy
-9.2% avg upside
8 analysts
$45.00
14.20% Upside
 +13.8% ·
PRVA
Privia Health Group
 Aug 10, 2026 BUY Strong Buy
+53.7% avg upside
26 analysts
$35.00
68.41% Upside
 -6.0% ·
COR
Cencora
 Aug 06, 2026 BUY Buy
+0.0% avg upside
45 analysts
$370.00
14.91% Upside
 +1.1% ·
ELAN
Elanco Animal Health
 Aug 06, 2026 BUY Strong Buy
+29.8% avg upside
18 analysts
$34.00
41.01% Upside
 +1.2% ·
HSIC
Henry Schein
 Aug 05, 2026 BUY Buy
+2.5% avg upside
25 analysts
$112.00
25.18% Upside
 +0.8% ·
BIO
Bio-Rad Laboratories
 Aug 05, 2026 HOLD Buy
-7.6% avg upside
9 analysts
$330.00
14.80% Downside
 +11.7% ·
IDXX
Idexx Laboratories
 Aug 05, 2026 HOLD Buy
+30.6% avg upside
17 analysts
$670.00
20.64% Upside
 -5.9% ·
MDLN
Medline
 Aug 05, 2026 BUY Strong Buy
+33.0% avg upside
27 analysts
$45.00
27.54% Upside
 -3.8% ·
TDOC
Teladoc
 Aug 03, 2026 HOLD Buy
+335.8% avg upside
38 analysts
$7.50
15.38% Upside
 -4.3% ·
WAY
Waystar Holding Corp.
 Aug 03, 2026 BUY Strong Buy
+41.5% avg upside
30 analysts
$28.00
6.71% Upside
 +11.8% ·
ALGN
Align Tech
 Aug 03, 2026 BUY Strong Buy
+88.5% avg upside
21 analysts
$240.00
52.31% Upside
 -7.7% ·
GMRS
GMR Solutions, Inc. Class A
 Jun 08, 2026 BUY Strong Buy
+48.9% avg upside
9 analysts
$17.00
34.97% Upside
 +18.8% ·
PHR
Phreesia
 May 28, 2026 HOLD Strong Buy
+41.1% avg upside
21 analysts
$12.00
1.19% Downside
 +25.5% ·
PAHC
Phibro Animal Health
 May 14, 2026 HOLD Sell
+5.5% avg upside
10 analysts
$44.00
16.89% Upside
 -1.9% ·
XRAY
DENTSPLY SIRONA
 May 06, 2026 SELL Buy
+160.3% avg upside
25 analysts
$10.50
5.55% Downside
 +0.2% ·
M
Macy's
 May 29, 2024 BUY Buy
+150.7% avg upside
35 analysts
 — -36.7% ·
SLQT
SelectQuote
 Sep 14, 2023 HOLD Buy
+1342.2% avg upside
16 analysts
$1.75
236.62% Upside
 +77.2% ·
MAX
MediaAlpha
 Aug 04, 2023 SELL Strong Buy
+40.8% avg upside
13 analysts
$8.00
37.76% Downside
 -83.2% ·
EHTH
Ehealth
 May 18, 2023 HOLD Hold
+1211.4% avg upside
19 analysts
$9.00
649.93% Upside
 -32.4% ·
BBLNF
Babylon Holdings
 Mar 09, 2023 HOLD Buy
+65549900.0% avg upside
6 analysts
$11.00
10999900.01% Upside
 · ·
GLSHQ
Gelesis Holdings
 Nov 15, 2022 HOLD Hold
+44999900.0% avg upside
1 analyst
$0.45
44999900.01% Upside
 · ·
AHCO
AdaptHealth
 Dec 11, 2019 BUY Strong Buy
+105.3% avg upside
13 analysts
$13.00
124.60% Upside
 +264.0% ·
PGNY
Progyny
 Nov 19, 2019 BUY Strong Buy
+27.5% avg upside
15 analysts
$28.00
7.78% Upside
 +9.3% ·
🔒 28 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Daniel Grosslight — Frequently Asked Questions
How accurate are Daniel Grosslight's stock ratings?
Based on the calls 13Foresight could measure, about 61% of Daniel's ratings were profitable over a one-year hold, with an average return of +8.9% per rating, or +5.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Daniel ranked on 13Foresight?
Daniel Grosslight is currently ranked #713 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Daniel cover?
Daniel most recently has ratings on HIMS, CAH, GDRX, EVH, ZTS, AGL, ACH, HCAT, MCK, NVST, CTEV, PRVA and 21 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.